Tamas Andras Koncz, MD, PhD 

Chief Medical Officer, Accord CMO at Pfizer and EMEA President at the Medical Affairs Professional Society (MAPS) 

He is an accomplished physician, health economist and pharmaceutical executive with over two decades of experience in medical affairs, clinical development, and healthcare access. Having been CMO for Pfizer’s Inflammation and Immunology Business and CMAO for International Developed Markets, Dr. Koncz now leads a novel initiative aimed at providing access to Pfizer’s entire portfolio of medicines and vaccines on a not-for-profit basis through Pfizer’s Accord for a Healthier World program in lower income countries. He also plays a key role in shaping the strategic direction of medical affairs as MAPS Board Director and EMEA President.

Earlier in his career, Dr. Koncz contributed to research on patient adherence and persistence, particularly with biologic and novel small molecule therapies for rheumatologic diseases. In his research and PhD thesis he emphasized how adherence influences clinical outcomes and real-world clinical and cost effectiveness.

His background includes leadership in inflammation and immunology, contributing to and publishing Phase 2 and Phase 3 clinical trials, contributions to patents and clinical trials related to COVID-19 therapies. As the medical leader of Pfizer’s Accord for a Healthier World, he is actively engaged with global, regional and national stakeholders on advancing access to treatments, building health-care capabilities and furthering clinical research in lower income countries.

Dr. Koncz holds an MD and PhD, along with advanced degrees in economics, health economics, and pharmaceutical medicine from leading European universities.

Jorge Cancela, PhD

Digital Health Leader at Roche

Jorge is a health tech enthusiast and innovator, passionate about building products that can unleash full human potential by preserving, extending and enhancing health. During the last years working at Roche, he took different product leadership roles for the oncology and neuroscience portfolio of remote patient monitoring and digital biomarkers solutions, leading end-to-end product strategy and lifecycle management, from early concept definition, business models articulation and building cross-functional teams to deliver regulatory-grade software as a medical device.

Before joining Roche, he was product manager at Merck KGaA for a software as a medical device solutions working in combination with a smart auto injector for growth hormone delivery and management, available in 45+ markets and recognised in the Pharmaceutical Marketing Excellence Awards (PMEA) 2017 Awards with Excellence in Innovation Award.
Prior to that, he was driving several international research health tech projects for different chronic conditions such as Parkinson's Disease and diabetes based on wearable technologies such as accelerometers and continuous glucose monitoring at the Universidad Politecnica de Madrid (UPM).

He is co-author of 40+ scientific publications in the digital health space. In 2015, he received the IDEA² Madrid Awardee from the Madrid-MIT M+Visión Consortium and a merit prize at the Young Investigator Award 2015 from the International Federation for Medical and Biological Engineering. Jorge is MBA (2017), PhD in Biomedical engineering (2016), M.Sc. degree in Telemedicine and Biomedical engineering (2010) and Telecommunications Engineer (2009) from the UPM. He was visiting researcher at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital (USA) in 2011, at the Duke-National University of Singapore (Singapore) in 2012 and at the Politecnico di Milano (Italy) in 2015.

Antoine Pironet, PhD

 Data Science Lead at AARDEX Group 

Antoine Pironet, PhD, is a medical data scientist with a deep focus on digital health, medication adherence, and the intersection of machine learning and real-world clinical data. With a PhD in Biomedical Engineering and over 10 years of experience in academic and industry settings, Antoine is passionate about transforming healthcare through data-driven innovation.

He currently serves as Data Science Lead at AARDEX Group, a global leader in digital solutions for medication adherence monitoring. In this role, Antoine spearheads research initiatives, develops advanced analytical models, and collaborates with international pharmaceutical companies and research institutions to optimize treatment outcomes using real-world adherence data.

Antoine’s research has been widely published in peer-reviewed journals, with contributions spanning medical informatics, patient behavior analytics, and computational modeling. His work aims to bridge the gap between clinical research and practical implementation, leveraging machine learning and behavioral science to support personalized, evidence-based care.

In addition to his technical expertise, Antoine is an advocate for transparent and reproducible research, and often mentors students and early-career professionals in the fields of health data science and digital health innovation.

Bernard Vrijens, PhD

Chief Executive Officer and Scientific Lead  at AARDEX Group 

Bernard Vrijens is the Chief Executive Officer at Advanced Analytical Research on Drug Exposure (AARDEX Group). In addition to his executive role at AARDEX, he also serves as a Professor of Biostatistics at the University of Liège in Belgium. He makes a significant contribution to academic research and to the advancement of evidence-based methodologies in medication adherence and clinical trial analytics during last 20 years.

Dr. Vrijens holds a PhD from the Department of Applied Mathematics and Informatics at Ghent University, Belgium.

He has pioneered a research program focused on a simple but robust taxonomy of common dosing errors, along with exploring optimal measurement-guided medication management that can drive adherence and maintain long-term persistence.

With over 100 peer-reviewed scientific papers and six patents to his name, Dr. Vrijens is also a founding member of the International Society for Medication Adherence (ESPACOMP) and an active member of several EU- and US-funded collaborative projects around the theme of adherence to medications.